Raymond James & Associates’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-797,677
| Closed | -$1.82M | – | 4130 |
|
|
2024
Q2 | $1.82M | Sell |
797,677
-5,158
| -0.6% | -$19.7K | ﹤0.01% | 2224 |
|
|
2024
Q1 | $3.47M | Buy |
802,835
+237,280
| +42% | +$827K | ﹤0.01% | 1816 |
|
|
2023
Q4 | $1.72M | Sell |
565,555
-360,221
| -39% | -$677K | ﹤0.01% | 2186 |
|
|
2023
Q3 | $1.33M | Buy |
925,776
+133,662
| +17% | +$259K | ﹤0.01% | 2272 |
|
|
2023
Q2 | $1.97M | Buy |
792,114
+44,703
| +6% | +$122K | ﹤0.01% | 2066 |
|
|
2023
Q1 | $2M | Buy |
747,411
+248,508
| +50% | +$1.19M | ﹤0.01% | 2034 |
|
|
2022
Q4 | $2.71M | Buy |
498,903
+19,268
| +4% | +$161K | ﹤0.01% | 1799 |
|
|
2022
Q3 | $5.99M | Buy |
479,635
+41,479
| +9% | +$474K | 0.01% | 1246 |
|
|
2022
Q2 | $2.16M | Buy |
438,156
+40,277
| +10% | +$223K | ﹤0.01% | 1934 |
|
|
2022
Q1 | $3.02M | Buy |
397,879
+166,564
| +72% | +$1.58M | ﹤0.01% | 1851 |
|
|
2021
Q4 | $2.36M | Buy |
231,315
+96,576
| +72% | +$1.23M | ﹤0.01% | 2058 |
|
|
2021
Q3 | $1.81M | Buy |
134,739
+2,091
| +2% | +$34.1K | ﹤0.01% | 2175 |
|
|
2021
Q2 | $2.91M | Buy |
132,648
+12,628
| +11% | +$281K | ﹤0.01% | 1850 |
|
|
2021
Q1 | $2.89M | Sell |
120,020
-24,933
| -17% | -$579K | ﹤0.01% | 1780 |
|
|
2020
Q4 | $2.61M | Sell |
144,953
-19,564
| -12% | -$292K | ﹤0.01% | 1737 |
|
|
2020
Q3 | $1.9M | Buy |
164,517
+11,729
| +8% | +$194K | ﹤0.01% | 1796 |
|
|
2020
Q2 | $3.71M | Buy |
152,788
+141,503
| +1,254% | +$2.34M | 0.01% | 1371 |
|
|
2020
Q1 | $124K | Buy |
11,285
+2,466
| +28% | +$46.1K | ﹤0.01% | 3168 |
|
|
2019
Q4 | $233K | Buy |
+8,819
| New | +$206K | ﹤0.01% | 3252 |
|
Raymond James & Associates's GTHX Position: Q3 2024 in Review
Raymond James & Associates sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 797,677 shares — an estimated $1.82M sold.
Raymond James & Associates first reported a position in GTHX in Q4 2019 and held it in 19 quarters. The position peaked at $5.99M in Q3 2022. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Raymond James & Associates reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Raymond James & Associates sold 797,677 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.82M.
- Raymond James & Associates first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2019 and held it in 19 quarters.
- Raymond James & Associates's G1 Therapeutics, Inc. Common Stock position peaked at $5.99M in Q3 2022.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.